Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
about
Regulation of Bim in Health and DiseaseTargeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysGossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.KLF4 overexpression and apigenin treatment down regulated anti-apoptotic Bcl-2 proteins and matrix metalloproteinases to control growth of human malignant neuroblastoma SK-N-DZ and IMR-32 cellsApoptosis in cancer: from pathogenesis to treatment.Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradationThe ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skinCDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family membersAn evidence-based review of obatoclax mesylate in the treatment of hematological malignanciespRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105.Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cellsVinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.Toward a cure for chronic lymphocytic leukemia: an attack on multiple frontsThe putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.Development of venetoclax for therapy of lymphoid malignancies.Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.Biomarkers of therapeutic response to BCL2 antagonists in cancer.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Apoptosis inducers in chronic lymphocytic leukemia.Small molecule Mcl-1 inhibitors for the treatment of cancer.New dimension in therapeutic targeting of BCL-2 family proteins.Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cellsTargeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy.Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines.BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.Microtubule destabilising agents: far more than just antimitotic anticancer drugs.The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimeticPlatinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum.Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
P2860
Q26781203-1E4C65DA-E392-4E4E-9F62-96B940038D36Q27853201-DBA9E204-EAEE-4E90-AA20-839F885DC4CFQ28077848-445F8880-9721-4E74-A720-DCAF8DB1F3A8Q33718487-E7A591B8-93C2-4005-9818-F33F94F6652CQ34547607-A6667A63-C094-4982-9D1D-9709BF6182B5Q35397889-D1CA4D49-8B71-463F-9262-86F3CAB359CAQ35543223-C3F90A93-2AB7-41A1-89D6-CD7A8CD91E9AQ35859229-301E0AD5-3CD0-4181-8ADE-E4FE11385419Q35880102-D5F0E9D9-6452-44FD-92F7-1A03E291777FQ35966223-A223EB97-963C-40CF-AD41-DFDA751F651AQ36170136-70A24785-EC61-4EE3-B76C-58EB34ED8CDFQ36245449-28CF7804-1D86-4465-BABF-5CD0D8D57100Q36601134-53EC64D3-50FB-47FD-88C8-70F60DBD356AQ36696524-01472356-B372-44E5-9F51-0F7938085D40Q36747304-D2170537-94DC-47D6-BBBC-62899159AAC3Q36751575-EA664B71-18F4-4082-B10E-AC8DFDBB426DQ36844333-69862B53-7AC9-44E5-A0E5-F567326F6F27Q37046690-A3F2E701-74C2-4321-9598-AFE21EC668A4Q37092954-1773F4A2-4356-494C-B4E6-8DC907B6A50FQ37542942-D9C92FB2-D337-4476-9FF8-5A28CA4E3307Q37626302-73E7CE73-3B70-4284-B73D-A2DEC287ED5CQ37657934-ED5ADE59-2A76-4EF3-A87B-FBB981B71ACBQ37702281-B639C040-8D71-4B22-8E2D-BAD8CA1A9193Q37997623-940859B7-3204-4FFD-B3B2-19871D5C6CD9Q38047846-D41E24A4-C5B4-45E9-B936-4C782D4CE2E3Q38115574-B3B22199-1C4C-4411-A207-444C625F1EC5Q38187815-0347CBB7-8C9C-4F78-8E49-40789D408FF7Q38244767-A42EAC56-EDC7-4A1C-A12D-8CCD492CE085Q38477617-12888817-4507-4EF0-B6B9-77B8FB5DF016Q38677019-F1FAA7B7-88C1-4DE6-8256-BDB47EF8CF72Q38850608-8EBC328F-7F32-4175-A70A-7FD5E2DA7233Q38881119-7712A0CE-9FEE-4E0F-83F5-5DBFC0A0DB83Q38909188-AE797235-7378-407C-B496-8EB1D6509E64Q38930539-1CDCFE0D-6CB9-40F2-B720-4091345E2361Q38952778-89C1675D-106F-4ACE-8821-12932933B7D6Q38976876-66BF8040-F293-4DD9-9B8B-A312DD783865Q39205781-36655C1A-4D6E-4FB4-BFA6-DFFFE9C522A3Q39267135-D0448EEA-9784-47B9-8CCE-A5F3B60BAC93Q39283973-ED17112F-84CC-4F67-B7CE-26D9F16D255FQ39360515-B6B94B30-023A-4FD4-8789-6F6D1DAFCEA1
P2860
Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Multiple BH3 mimetics antagoni ...... ulating BH3-only protein NOXA.
@ast
Multiple BH3 mimetics antagoni ...... ulating BH3-only protein NOXA.
@en
type
label
Multiple BH3 mimetics antagoni ...... ulating BH3-only protein NOXA.
@ast
Multiple BH3 mimetics antagoni ...... ulating BH3-only protein NOXA.
@en
prefLabel
Multiple BH3 mimetics antagoni ...... ulating BH3-only protein NOXA.
@ast
Multiple BH3 mimetics antagoni ...... ulating BH3-only protein NOXA.
@en
P2093
P2860
P356
P1476
Multiple BH3 mimetics antagoni ...... ulating BH3-only protein NOXA.
@en
P2093
Alan Eastman
Alexandre A Pletnev
Alexei F Kisselev
Bethany L Salerni
Darcy J P Bates
Ryan S Soderquist
Tina C Albershardt
P2860
P304
24882-24895
P356
10.1074/JBC.M111.255828
P407
P577
2011-05-31T00:00:00Z